Enzyme proves viable drug target for deadly Epstein-Barr virus infections in Duncan's Disease patients

For certain genetic disorders, an infection can trigger an overly aggressive immune response that does more harm than good to the patient. New research suggests that targeting a single enzyme could put the brakes on a lethal immune response triggered by Epstein-Barr virus (EBV) in patients with X-linked lymphoproliferative disease (XLP-1).

from Today's Healthcare News -- ScienceDaily http://ift.tt/1lp9uDl